Digestive system perforations after anterior cervical spine surgery (ACSS), if left untreated, are life-threatening. These injuries are often categorized as pharyngoesophageal. Although the pharynx and esophagus are continuations of each other, they are two distinct anatomical structures. There is limited experience in managing patients with pharyngeal injuries after ACSS. Using PRISMA guidelines, a PubMed search was conducted on the iatrogenic pharyngeal perforations after ACSS for the treatment of disc herniation and degenerative cervical myeloradiculopathy. A total of 12 patients met our inclusion criteria. Eleven were from published studies, and one was our patient (2 female and 10 male, mean age = 56.25 years, range: 31–82 years). Clinical symptoms of patients with iatrogenic pharyngeal perforation after ACSS varied depending on whether the cases present early or late after surgery. Although clinical symptoms suggested a pharynx or esophageal injury, definitive diagnosis was challenging. All cases diagnosed either early or late after ACSS underwent surgical repair treatment, except for one case managed conservatively with antibiotics and nasogastric feeding. The overall outcome was favorable for all patients. However, the postoperative follow-up duration was not specified in two cases. In the remaining 10 cases, postoperative follow-up durations were generally short and varied significantly (mean = 4.87 months, median = 1.75 months, range:1 week–24 months). Iatrogenic pharyngeal injuries resulting from ACSS are extremely rare. They are relatively straightforward to diagnose and can be managed with a multidisciplinary approach. However, their long-term prognosis remains unknown.
15 May 2022 in Turkish Journal of Gastroenterology
Background: Hepatitis C is one of the leading causes of death in patients with inherited bleeding disorders. Currently, direct-acting antiviral drugs used for the treatment of hepatitis C have become an effective and a reliable option for people with inherited bleeding disorders. The aim of this study is to report the efficacy and safety of ombitasvir + paritaprevir/ritonavir and dasabuvir combination in the treatment of hepatitis C in patients with inherited bleeding disorders. Methods: In this retrospective study, we evaluated the efficacy and safety of the combination of ombitasvir + paritaprevir/ritonavir and dasabuvir in 10 adult patients with hemophilia A, 4 patients with hemophilia B, and 1 patient with von Willebrand disease who were infected with hepatitis C genotype 1. Results: Five patients had genotype 1a and 10 patients had genotype 1b chronic hepatitis C. One patient had Child A cirrhosis, 14 patients had chronic hepatitis C without cirrhosis. Hepatitis C virus ribonucleic acid was negative in all patients at week 4 and at the end of the treatment. Sustained virologic response was obtained in all patients. Serious side effects were detected in 3 patients, which were intra- muscular bleeding, erosive gastritis-related gastrointestinal bleeding, and pneumonia. Conclusion: Ombitasvir + paritaprevir combined with ritonavir and dasabuvir ± ribavirin is an effective treatment for patients infected with genotype 1 hepatitis C who have coagulation disorders. Tolerance and side effects are similar to other treatment options. Cite this article as: Sonsuz A, Bozcan S, Hatemi İ, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin combinations in patients with genotype 1 hepatitis C and inherited bleeding disorders. Turk J Gastroenterol. 2022;33(5):414-420.